Cerebrolysin

Benefits

About Cerebrolysin

Cerebrolysin is a porcine brain-derived peptide preparation manufactured by EVER Neuro Pharma. It contains a standardized mixture of low-molecular-weight neuropeptides (approximately 25% by weight) and free amino acids (approximately 75%) obtained through controlled enzymatic proteolysis of purified porcine brain proteins. The active peptide fraction includes fragments that mimic the activity of endogenous neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF). Cerebrolysin has been used clinically in over 40 countries — primarily in Europe, Asia, and Latin America — for the treatment of acute ischemic stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia. It is not FDA-approved in the United States and remains classified as a research compound in that market. Multiple randomized, double-blind, placebo-controlled trials have demonstrated improvements in cognitive function, global clinical outcomes, and neurological recovery scores in patients with mild-to-moderate Alzheimer's disease and post-stroke populations. The preparation is administered by intramuscular injection (for volumes up to 5 mL) or by slow intravenous infusion (for volumes above 5 mL, diluted in standard saline). Treatment protocols typically run 10 to 21 consecutive days, followed by rest periods of 3 to 6 months. Courses may be repeated two to four times per year depending on clinical response. Within the nootropic and biohacking community, Cerebrolysin is primarily sought for its neurotrophic and neuroprotective properties — particularly its ability to increase BDNF, promote synaptogenesis, and support neuronal survival under conditions of oxidative stress or age-related decline.

Who Should Consider Cerebrolysin

• Stroke recovery patients
• Individuals with mild-to-moderate Alzheimer's disease
• Traumatic brain injury recovery
• Vascular dementia patients
• Adults seeking cognitive enhancement and neuroprotection
• Aging individuals concerned about neurodegenerative decline

How Cerebrolysin Works

Cerebrolysin exerts its effects through a multimodal mechanism that mirrors the activity of endogenous neurotrophic factors. The low-molecular-weight peptide fraction crosses the blood-brain barrier and activates the same intracellular signaling cascades as BDNF, NGF, GDNF, and CNTF — primarily the PI3K/Akt and MAPK/ERK pathways. This activation promotes neuronal survival by upregulating anti-apoptotic proteins (Bcl-2) and suppressing pro-apoptotic signals (caspase-3). Cerebrolysin stimulates neurite outgrowth and synaptogenesis, increasing dendritic spine density in hippocampal and cortical neurons. It modulates neurotransmitter systems including acetylcholine, dopamine, and serotonin, which underlies its effects on memory consolidation and cognitive processing. The preparation also reduces neuroinflammation by inhibiting microglial activation and downregulating pro-inflammatory cytokines (TNF-alpha, IL-1-beta). In ischemic conditions, it provides neuroprotection by attenuating glutamate-induced excitotoxicity and scavenging reactive oxygen species.

What to Expect

Dosing Protocol

Note: Porcine brain-derived peptide preparation (215.2 mg/mL). Pre-filled solution — no reconstitution needed. Administer IM (up to 5 mL) or IV (above 5 mL). Run as a 10-21 day course with 3-6 month breaks. NOT FDA-approved in the US but approved in 40+ countries. Morning dosing preferred.

How to Inject Cerebrolysin

Cerebrolysin is a ready-to-use solution at 215.2 mg/mL — no reconstitution needed. For volumes up to 5 mL (1,076 mg), administer by intramuscular injection into the deltoid or gluteal muscle. For volumes above 5 mL, administer by slow intravenous infusion diluted in 100-250 mL of 0.9% sodium chloride or Ringer's solution over 15-60 minutes. Do not mix with balanced amino acid infusion solutions. Morning administration is preferred. Inject slowly when using the IM route. Rotate injection sites.

Cycling Protocol

Pharmacokinetics

Side Effects

Generally well-tolerated in clinical trials, with adverse event rates similar to placebo. The most commonly reported side effects include dizziness or vertigo, headache, nausea, sweating, and injection site reactions (pain, redness, or swelling). Agitation and a feeling of warmth have been reported at higher IV doses. Transient flu-like symptoms may occur during the first few days of treatment. Serious adverse events are rare.

Contraindications

Drug Interactions

Storage & Stability

Related Peptides

Selank

Cognitive

Semax

Cognitive

References

1. Cerebrolysin: a review of its use in dementiaReview
2. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trialsPubMed 22514795
3. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trialsPubMed 25832905
4. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trialPubMed 20656516
5. Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trialsPubMed 29248999
6. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disordersReview